Ph3 Study to dostarlimab in patients with advanced HNSCC
Phase III Clinical Trial
Protocol 221530 A Randomized Double-blind Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma